4.6 Article

Kallikrein-related Peptidase 5 Functions in Proteolytic Processing of Profilaggrin in Cultured Human Keratinocytes

期刊

JOURNAL OF BIOLOGICAL CHEMISTRY
卷 288, 期 24, 页码 17179-17189

出版社

AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
DOI: 10.1074/jbc.M113.476820

关键词

-

资金

  1. Hamamatsu University School of Medicine [101337]
  2. Ministry of Education, Culture, Sports, Science, and Technology [24890082, 24659525]
  3. Grants-in-Aid for Scientific Research [24890082, 24659525, 24791180] Funding Source: KAKEN

向作者/读者索取更多资源

Filaggrin protein is synthesized in the stratum granulosum of the skin and contributes to the formation of the human skin barrier. Profilaggrin is cleaved by proteolytic enzymes and converted to functional filaggrin, but its processing mechanism remains not fully elucidated. Kallikrein-related peptidase 5 (KLK5) is a major serine protease found in the skin, which is secreted from lamellar granules following its expression in the stratum granulosum and activated in the extracellular space of the stratum corneum. Here, we searched for profilaggrin-processing protease(s) by partial purification of epidermal extracts and found KLK5 as a possible candidate. We used high performance liquid chromatography coupled with electrospray tandem mass spectrometry to show that KLK5 cleaves profilaggrin. Furthermore, based on a proximity ligation assay, immunohistochemistry, and immunoelectron microscopy analysis, we reveal that KLK5 and profilaggrin co-localize in the stratum granulosum in human epidermis. KLK5 knockdown in normal cultured human epidermal keratinocytes resulted in higher levels of profilaggrin, indicating that KLK5 potentially functions in profilaggrin cleavage.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Infectious Diseases

The second nationwide surveillance of antibacterial susceptibility patterns of pathogens isolated from skin and soft-tissue infections in dermatology departments in Japan

Takamitsu Ohnishi, Shinichi Watanabe, Tetsuya Matsumoto, Hiroshi Yotsuyanagi, Junko Sato, Intestu Kobayashi, Shin Iinuma, Takashi Nagayama, Shuichiro Shibuya, Natsuki Ogawa, Ken Iozumi, Yasuyuki Nakajima, Yukiko Kurikawa, Motoko Kobayashi, Koma Matsuo, Hideyuki Ishikawa, Tadamichi Shimizu, Kiyohiro Tsutsui, Tatsuyoshi Kawamura, Ryuhei Okuyama, Mariko Seishima, Yoichi Akita, Chikatoshi Kasugai, Katsuaki Yano, Yasuhiko Tamada, Kimihiko Mizutani, Kenji Kabashima, Nanako Yamada, Masami Ikeda

Summary: The present study compared trends in antimicrobial resistance patterns in pathogens isolated from skin and soft-tissue infections (SSTIs) in Japan with those of a nationwide survey conducted in 2013. The prevalence of methicillin-resistant Staphylococcus aureus (MRSA) did not differ significantly between the present study and the 2013 survey. However, the prevalence of methicillin-resistant coagulase-negative staphylococci (MRCNS) was higher in the present study compared to the 2013 survey. The susceptibility profiles of MRSA and MRCNS to various antibiotics were not significantly different between the two surveys. Continuous monitoring is important for guiding the appropriate treatment of SSTIs.

JOURNAL OF INFECTION AND CHEMOTHERAPY (2023)

Letter Dermatology

Non-invasive visualization of epidermal hypertrophy of pachydermoperiostosis

Takayoshi Komatsu-Fujii, Corrine Sison de Jesus, Takashi Nomura, Kenji Kabashima

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Letter Dermatology

Interleukin-13 inhibition by tralokinumab reduces inducible T-cell costimulator-positive innate lymphoid cells in skin lesions of atopic dermatitis

Toshiaki Kogame, Satoru Yonekura, Paola Lovato, Masahiro Hirata, Riko Takimoto-ito, Tomoya Takegami, Takayoshi Komatsu-Fujii, Naotomo Kambe, Takashi Nomura, Mads A. Ropke, Kenji Kabashima

Summary: Despite the limited sample size and low frequency of skin ILCs in this study, the data suggest that ICOS+ ILCs express IL-13Ra1 and that the density of ICOS+ ILCs decreases after four weeks of tralokinumab treatment.

BRITISH JOURNAL OF DERMATOLOGY (2023)

Article Dermatology

Increased type I interferon expression from T cells in lesional skin of Degos disease

Yuki Honda Keith, Atsushi Otsuka, Toshiaki Kogame, Hiroyuki Ito, Shunya Usui, Masakazu Fujimoto, Keita Jinnouchi, Masahiro Hirata, Kazumitsu Sugiura, Kenji Kabashima

JOURNAL OF DERMATOLOGY (2023)

Letter Dermatology

A case of Kimura disease with atopic dermatitis successfully treated with baricitinib

Marina Ueda, Toshiaki Kogame, Gyohei Egawa, Naotomo Kambe, Kenji Kabashima

JOURNAL OF DERMATOLOGY (2023)

Article Dermatology

English version of Japanese guidance for the use of oral Janus kinase (JAK) inhibitors in the treatments of atopic dermatitis

Hidehisa Saeki, Masashi Akiyama, Masatoshi Abe, Atsuyuki Igarashi, Shinichi Imafuku, Yukihiro Ohya, Norito Katoh, Hideto Kameda, Kenji Kabashima, Yuichiro Tsunemi, Michihiro Hide, Mamitaro Ohtsuki

Summary: This guidance provides information on the use of oral JAK inhibitors for the treatment of atopic dermatitis. It explains the role of oral JAK inhibitors in inhibiting the signal transduction of cytokines involved in the pathogenesis of atopic dermatitis. It also highlights the authorized oral JAK inhibitors for atopic dermatitis in Japan and emphasizes the importance of considering disease factors, treatment factors, and patient backgrounds in the selection of treatment options.

JOURNAL OF DERMATOLOGY (2023)

Review Dermatology

Estimands for atopic dermatitis clinical trials: Expert opinion on the importance of intercurrent events

R. Bissonnette, L. F. Eichenfield, E. Simpson, D. Thaci, K. Kabashima, J. P. Thyssen, E. Guttman-Yassky, F. P. Nunes, M. Gamalo, F. Ahmad, M. Kuligowski, K. Sun, C. Pipper, A. W. Christensen, P. D'Angelo, M. Milutinovic, A. Guettner, J. I. Silverberg

Summary: Despite the lack of guidelines for analyzing clinical trial data in atopic dermatitis (AD), using the estimand framework can help standardize the analysis and incorporate intercurrent events. Intercurrent events, such as rescue therapy and sleep deprivation, frequently occur in AD trials and their inconsistent handling limits result interpretation. Applying the estimand framework, as guided by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH), can improve AD trial design and analysis by providing more reflective and informative results for clinicians to make treatment selection.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Article Medicine, General & Internal

An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study

Emma Guttman-Yassky, Eric L. Simpson, Kristian Reich, Kenji Kabashima, Ken Igawa, Tetsuya Suzuki, Hirotaka Mano, Takeshi Matsui, Ehsanollah Esfandiari, Masutaka Furue

Summary: This study evaluated the efficacy and safety of the anti-OX40 antibody rocatinlimab in patients with moderate-to-severe atopic dermatitis. The results showed significant reductions in EASI score at week 16 in patients receiving rocatinlimab compared to placebo. The treatment led to progressive improvements in atopic dermatitis, which were maintained in most patients after treatment discontinuation, and it was well tolerated.

LANCET (2023)

Article Dermatology

Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis A Post Hoc Analysis of 6 Randomized Clinical Trials

Amy S. Paller, Jonathan I. Silverberg, Michael J. Cork, Emma Guttman-Yassky, Benjamin Lockshin, Alan D. Irvine, Moon Bum Kim, Kenji Kabashima, Zhen Chen, Yufang Lu, Ashish Bansal, Ana B. Rossi, Arsalan Shabbir

Summary: This study assessed the efficacy and safety of dupilumab in patients with severe erythrodermic atopic dermatitis (AD). The results showed that dupilumab significantly improved AD signs and symptoms, including affected body surface area, Eczema Area and Severity Index (EASI) score, and Pruritus Numerical Rating Scale (PP-NRS) score. The treatment also led to reductions in serum biomarker levels.

JAMA DERMATOLOGY (2023)

Letter Dermatology

A Japanese case of Vorner-type palmoplantar keratoderma caused by a novel KRT1 variant

Satoshi Nakamizo, Teruasa Murata, Yoshihiro Ishida, Satomi Aoki, Takashi Sasaki, Akiharu Kubo, Kenji Kabashima

JOURNAL OF DERMATOLOGY (2023)

Article Pathology

Cutaneous arteritis with intimal fibrin ring and immature myeloid cell infiltrate: lymphocytic thrombophilic arteritis or histiocytoid polyarteritis nodosa?

Masakazu Fujimoto, Toshiya Miyake, Yo Kaku, Masahiro Hirata, Kenji Kabashima, Hironori Haga

Summary: This study aimed to resolve the ongoing debate on whether lymphocytic thrombophilic arteritis (LTA) is a separate disease or a type of polyarteritis nodosa (PAN). Immunohistochemistry analysis of skin biopsies from five LTA patients revealed that the majority of infiltrating cells were myelomonocytic cells rather than lymphocytes. Based on these findings, PAN was considered a more appropriate diagnosis for the five cases. Further investigation is needed to determine if histiocytoid PAN with immature myeloid cells is the same disease as conventional PAN with mature neutrophils.

VIRCHOWS ARCHIV (2023)

Article Dermatology

Nemolizumab Improves Patient-Reported Symptoms of Atopic Dermatitis with Pruritus: Post Hoc Analysis of a Japanese Phase III Randomized Controlled Trial

Kenji Kabashima, Takayo Matsumura, Hiroshi Komazaki, Makoto Kawashima

Summary: This study investigated the impact of nemolizumab on the quality of life in patients with atopic dermatitis. The results showed that nemolizumab treatment improved sleep quality, interpersonal relationships, and work activities.

DERMATOLOGY AND THERAPY (2023)

Article Biochemistry & Molecular Biology

Mead acid inhibits retinol-induced irritant contact dermatitis via peroxisome proliferator-activated receptor alpha

Azusa Saika, Prabha Tiwari, Takahiro Nagatake, Eri Node, Koji Hosomi, Tetsuya Honda, Kenji Kabashima, Jun Kunisawa

Summary: Mead acid can suppress retinol-induced irritant contact dermatitis and prevent keratinocyte hyperproliferation and the expression of neutrophil chemoattractants through the PPAR-alpha pathway.

FRONTIERS IN MOLECULAR BIOSCIENCES (2023)

Review Immunology

Exploring the role of Janus kinase (JAK) in atopic dermatitis: a review of molecular mechanisms and therapeutic strategies

Toshiaki Kogame, Gyohei Egawa, Kenji Kabashima

Summary: Recent studies have shown that Janus kinase (JAK) plays a crucial role in signal transduction for inflammatory diseases like atopic dermatitis (AD). Clinical trials using JAK inhibitors and biologic reagents have been successful in treating AD, indicating the efficacy of molecular-based therapies. However, there are concerns about the safety of JAK inhibitors, including severe heart disease. This article provides an overview of the molecular mechanisms of AD and discusses JAK-related biology as a target for AD treatment.

IMMUNOLOGICAL MEDICINE (2023)

Article Dermatology

Neutrophilic epitheliotropism, proposed as an auto-inflammatory condition of neutrophilic urticarial dermatosis including Schnitzler syndrome, is also observed in Japanese cases

Hitomi Nakaizumi, Naotomo Kambe, Hiroyuki Irie, Yo Kaku, Masakazu Fujimoto, Hajime Yoshifuji, Yasuhiro Kazuma, Kazumoto Katagiri, Takuro Kanekura, Kenji Kabashima

Summary: Schnitzler syndrome (SchS) is a rare autoinflammatory disease characterized by bone pain, recurrent fever, and other symptoms. A key feature of the syndrome is the presence of a persistent urticarial-like rash. Histopathological data suggests that neutrophilic epitheliotropism, or the tendency of neutrophils to infiltrate and affect epithelial tissue, can be a useful marker for diagnosing SchS and differentiating it from conventional urticaria. Understanding this characteristic is crucial for early diagnosis and appropriate treatment.

JOURNAL OF DERMATOLOGY (2023)

暂无数据